Chinese herbal medicine for recurrent urinary tract infection: formulation-specific clinical evidence, experimental pharmacology, and unresolved recurrence mechanisms
- 1Beijing Tsinghua Changgung Hospital, Tsinghua University
Abstract
Ethnopharmacological relevance: Chinese herbal medicine (CHM) is used for recurrent or chronic urinary symptoms within the traditional category of dysuria, often through stage-specific treatment during symptomatic and remission phases. Whether defined CHM preparations prevent recurrent bacterial cystitis or modify recurrence biology remains uncertain. The aim of this study is to critically evaluate formulation-specific clinical evidence for CHM in women with recurrent urinary tract infection (rUTI) and determine whether reported benefits are connected to recurrence biology.
Materials and methods: Structured searches of PubMed, China National Knowledge Infrastructure, and Wanfang Data were closed on 13 July 2026. After within-batch screening and cross-source reconciliation, 103 reports were linked into 96 study or unresolved-report clusters. Clusters were classified by directness, and clinical confidence was appraised using allocation, participant flow, recurrence ascertainment, denominator integrity, comparator, intervention identity, safety reporting, internal consistency, and report independence.
Results: Ten core clusters directly addressed prospective recurrence or suppressive treatment, but every comparative estimate was of very low confidence. Reported signals were formulation-specific and were limited by attrition, responder-conditioned denominators, active comparators, co-interventions, poorly defined recurrence, internal numerical inconsistencies, or report linkage. Botanical identity and study-batch chemistry were usually inadequate. Experimental studies supported anti-adhesion, virulence-modulating, anti-inflammatory, immune, and urothelial plausibility, including chemically characterized Persicaria capitata extract and more specific Caveolin-1 evidence for purified cynaroside, but predominantly used acute or pretreatment models. No microbiome or biomarker study evaluated clinical mediation.
Conclusion: Current evidence is inconclusive rather than uniformly negative and supports cautious hypothesis generation for specific preparations, not a class-wide efficacy or safety claim. No clinical study demonstrates that CHM reduces recurrence by clearing persistent uropathogens, interrupting gut–bladder or vaginal transmission, restoring microbial ecology, or repairing the urothelial barrier. Reproducible products, intention-to-treat recurrence trials, longitudinal strain-resolved sampling, and prespecified mediation analyses are required.
Related
- Study on the Active Constituents and Underlying Mechanisms of Renshen Yangying Decoction Against Angina Pectoris Based on Integrated Serum Pharmacochemistry, Network Pharmacology, Molecular Docking, and Experimental Validation
- Unraveling the multitarget mechanisms of aloe emodin against periodontitis: a synergy of network pharmacology and experimental validation
- Unraveling the therapeutic mechanisms of placenta hominis for polycystic ovary syndrome through network pharmacology, molecular docking, and experimental validation
- Network pharmacology and experimental validation reveal the anti-inflammatory mechanisms of andrographolide in the treatment of periodontitis.
- Exploring the potential mechanisms of Pei Yuan Yi Fei decoction for non-small cell lung cancer through network pharmacology and experimental validation
BibTeX
@article{zhang2026chinese,
title = {{Chinese herbal medicine for recurrent urinary tract infection: formulation-specific clinical evidence, experimental pharmacology, and unresolved recurrence mechanisms}},
author = {Pengtian Zhang and Xuming Zhang and Chaoyue Ji and Weiguo Hu},
journal = {Frontiers in Pharmacology},
year = {2026},
month = oct,
doi = {10.3389/fphar.2026.1950004},
url = {https://www.frontiersin.org/articles/10.3389/fphar.2026.1950004/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Chinese herbal medicine for recurrent urinary tract infection: formulation-specific clinical evidence, experimental pharmacology, and unresolved recurrence mechanisms
AU - Pengtian Zhang
AU - Xuming Zhang
AU - Chaoyue Ji
AU - Weiguo Hu
PY - 2026
DA - 2026/10/23
JO - Frontiers in Pharmacology
DO - 10.3389/fphar.2026.1950004
UR - https://www.frontiersin.org/articles/10.3389/fphar.2026.1950004/full
AB - Ethnopharmacological relevance: Chinese herbal medicine (CHM) is used for recurrent or chronic urinary symptoms within the traditional category of dysuria, often through stage-specific treatment during symptomatic and remission phases. Whether defined CHM preparations prevent recurrent bacterial cystitis or modify recurrence biology remains uncertain. The aim of this study is to critically evaluate formulation-specific clinical evidence for CHM in women with recurrent urinary tract infection (rUTI) and determine whether reported benefits are connected to recurrence biology. Materials and methods: Structured searches of PubMed, China National Knowledge Infrastructure, and Wanfang Data were closed on 13 July 2026. After within-batch screening and cross-source reconciliation, 103 reports were linked into 96 study or unresolved-report clusters. Clusters were classified by directness, and clinical confidence was appraised using allocation, participant flow, recurrence ascertainment, denominator integrity, comparator, intervention identity, safety reporting, internal consistency, and report independence. Results: Ten core clusters directly addressed prospective recurrence or suppressive treatment, but every comparative estimate was of very low confidence. Reported signals were formulation-specific and were limited by attrition, responder-conditioned denominators, active comparators, co-interventions, poorly defined recurrence, internal numerical inconsistencies, or report linkage. Botanical identity and study-batch chemistry were usually inadequate. Experimental studies supported anti-adhesion, virulence-modulating, anti-inflammatory, immune, and urothelial plausibility, including chemically characterized Persicaria capitata extract and more specific Caveolin-1 evidence for purified cynaroside, but predominantly used acute or pretreatment models. No microbiome or biomarker study evaluated clinical mediation. Conclusion: Current evidence is inconclusive rather than uniformly negative and supports cautious hypothesis generation for specific preparations, not a class-wide efficacy or safety claim. No clinical study demonstrates that CHM reduces recurrence by clearing persistent uropathogens, interrupting gut–bladder or vaginal transmission, restoring microbial ecology, or repairing the urothelial barrier. Reproducible products, intention-to-treat recurrence trials, longitudinal strain-resolved sampling, and prespecified mediation analyses are required.
SN - 1663-9812
ER -